Eli Lilly shares are trading lower. The stock may be reacting to FDA approval of Biogen's Alzheimer's drug.
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's shares are trading lower, potentially in response to the FDA's approval of Biogen's Alzheimer's drug.
July 07, 2023 | 6:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's stock is trading lower, potentially due to the FDA's approval of a competing Alzheimer's drug by Biogen.
The FDA's approval of Biogen's Alzheimer's drug could potentially increase competition for Eli Lilly in the Alzheimer's treatment market, which may negatively impact their stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100